What is the reported value and structure of Warburg Pincus's potential acquisition of PANTHERx Rare?

According to the Wall Street Journal, Warburg Pincus is nearing a deal to acquire PANTHERx Rare for more than $7 billion, including debt, and is partnering with Abu Dhabi Investment Authority on the acquisition; the report notes that nothing is finalized and timing could still slip.

What is PANTHERx Rare's business focus and ownership history leading up to this potential deal?

PANTHERx Rare is a Pittsburgh-based specialty pharmacy company that specializes in providing medicines and patient support services for rare and orphan diseases; it was acquired by Centene in 2020, sold by Centene in 2022 to a consortium including General Atlantic, Nautic Partners, and The Vistria Group, and remains owned by that investor group ahead of the potential Warburg Pincus deal.

Warburg Pincus Nears $7 Billion Deal for PANTHERx Rare, WSJ Reports

Jul 10, 2026

Warburg Pincus is nearing a $7 billion acquisition of specialty pharmacy firm PANTHERx Rare alongside Abu Dhabi Investment Authority. The potential deal underscores rising private equity activity in the healthcare sector.

reuters

2026-07-10

Warburg Pincus Nears $7 Billion Deal for PANTHERx Rare, WSJ Reports

FAQ

Scan to get the App